TY - JOUR
T1 - Anti-tumoral effects of somatostatin analogs
T2 - a lesson from the CLARINET study
AU - Albertelli, M.
AU - Nazzari, E.
AU - Sciallero, S.
AU - Grillo, F.
AU - Morbelli, S.
AU - De Cian, F.
AU - Cittadini, G.
AU - Ambrosetti, E.
AU - Ciarmiello, A.
AU - Ferone, D.
AU - On behalf of the IRCCS Policlinico San Martino, University of Genova Neuroendocrine Tumor Board
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Octreotide and lanreotide, the first-generation somatostatin analogs, successfully control hormone hyperproduction, and related syndromes, in patients with acromegaly and neuroendocrine tumors. However, their anti-tumor effect, rather evident in large number of pituitary adenomas in acromegalic patients, has been hypothesized for a long time in patients with neuroendocrine tumors as well, although a significant tumor shrinkage has rarely been observed. However, the recent publication of the CLARINET study has strengthened the evidence, already emerged with the PROMID trial, that the long-term treatment with the first-generation long-acting somatostatin analogs may exert an anti-tumor activity on G1 and G2 enteropancreatic neuroendocrine tumors, as well. After the publication, majority of international guidelines have updated their algorithms in line with these results and this class of drugs obtained the indication as anti-tumor agents in the majority of patients with neuroendocrine tumors.
AB - Octreotide and lanreotide, the first-generation somatostatin analogs, successfully control hormone hyperproduction, and related syndromes, in patients with acromegaly and neuroendocrine tumors. However, their anti-tumor effect, rather evident in large number of pituitary adenomas in acromegalic patients, has been hypothesized for a long time in patients with neuroendocrine tumors as well, although a significant tumor shrinkage has rarely been observed. However, the recent publication of the CLARINET study has strengthened the evidence, already emerged with the PROMID trial, that the long-term treatment with the first-generation long-acting somatostatin analogs may exert an anti-tumor activity on G1 and G2 enteropancreatic neuroendocrine tumors, as well. After the publication, majority of international guidelines have updated their algorithms in line with these results and this class of drugs obtained the indication as anti-tumor agents in the majority of patients with neuroendocrine tumors.
KW - Anti-tumor effect
KW - Clinical trial
KW - Lanreotide
KW - Neuroendocrine tumors
KW - Octreotide
KW - Somatostatin analogs
UR - http://www.scopus.com/inward/record.url?scp=85019739770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019739770&partnerID=8YFLogxK
U2 - 10.1007/s40618-017-0692-0
DO - 10.1007/s40618-017-0692-0
M3 - Article
AN - SCOPUS:85019739770
VL - 40
SP - 1265
EP - 1269
JO - Journal of Endocrinological Investigation
JF - Journal of Endocrinological Investigation
SN - 0391-4097
IS - 11
ER -